Trials / Completed
CompletedNCT05488613
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) With a Focus on Patients Treated With Rydapt (Midostaurin) in Helsinki and Uusimaa Hospital District
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 81 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.
Detailed description
Adult patients (18 years or older) with the inclusion diagnosis, AML (ICD-10 C92.0), between 1.1.2013 - 30.6.2020 were followed from the index date (first ever record of the inclusion diagnosis) until the end of follow-up (30.6.2020), or death. This study did not involve any contacts to patients. The study inclusion period was changed from 1.1.2013 - 30.6.2020 specified in the protocol to 1.1.2016 - 30.6.2020 due to lack of medication data from pre-2016.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midostaurin | Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily. |
Timeline
- Start date
- 2020-09-24
- Primary completion
- 2021-01-26
- Completion
- 2021-01-26
- First posted
- 2022-08-04
- Last updated
- 2022-11-08
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT05488613. Inclusion in this directory is not an endorsement.